Risk factors and treatment for recurrent vulvar squamous cell carcinoma

25Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Recurrent disease occurs in 12–37% of patients with vulvar squamous cell carcinoma (VSCC). Decisions about treatment of recurrent VSCC mainly depend on the location of the recurrence and previous treatment, resulting in individualized and consensus-based approaches. Most recurrences (40–80%) occur within 2 years after initial treatment. Currently, wide local excision is the treatment of choice for local recurrences. Isolated local recurrence of VSCC has a good prognosis, with reported 5-year survival rates of up to 60%. Groin recurrences and distant recurrences are less common and have an extremely poor prognosis. For groin recurrences, surgery with or without (chemo) radiotherapy is a treatment option, depending on prior treatment. For distant recurrences, there are only palliative treatment options. In this review, we give an overview of the available literature and discuss epidemiology, risk factors, and prognostic factors for the different types of recurrent VSCC and we describe treatment options and clinical outcome.

Cite

CITATION STYLE

APA

Nooij, L. S., Brand, F. A. M., Gaarenstroom, K. N., Creutzberg, C. L., de Hullu, J. A., & van Poelgeest, M. I. E. (2016, October 1). Risk factors and treatment for recurrent vulvar squamous cell carcinoma. Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd. https://doi.org/10.1016/j.critrevonc.2016.07.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free